Find a Diabetes Drug Lawyer
*Takeda Pharmaceutical Company has agreed to pay $2.4 billion to settle claims that its diabetes drug is linked to bladder cancer.*
Millions of people live with diabetes and depend on medications to help regulate their blood sugar levels. However, research has found some popular diabetes drugs may be linked to an increased risk of bladder cancer.
A 2012 study published in the Journal of the National Cancer Institute found patients taking pioglitazone (Actos) or rosiglitazone (Avandia) were 2-3 times more likely to develop bladder cancer than those taking a different class of drugs.
Concern about these drugs is so serious that France and Germany suspended the sale of Actos in their counties in 2011.
In the United States, the FDA issued a warning about bladder cancer risk for the following medications:
- Actos Met
- Actos Met XR
Were you diagnosed with bladder cancer after taking one of these drugs?
Takeda Pharmaceutical Company, the manufacturer of Actos, recently agreed to pay up to $2.4 billion to settle 9,000 lawsuits filed by patients who developed bladder cancer.
Bladder cancer can result in medical bills, lost income, stress and anxiety. Talk to a diabetes drug lawyer to determine whether you may be eligible for monetary compensation.
Sometimes in the rush to get new drugs on the market, it seems as though serious side effects are overlooked.
That could be the case with the latest class of diabetes drugs: SGLT2 Inhibitors.
The FDA has warned SGLT2 Inhibitors may lead the body to create a dangerous level of blood acid, a condition called ketoacidosis that may require hospitalization.
Were you admitted to the hospital after taking one of the following medicines?
If so, you may want to talk to a SGLT2 Inhibitor lawyer.
Legal professionals are currently working to assess whether drug manufacturers may be held responsible for complications, such as ketoacidosis, which could be linked to the use of SGLT2 Inhibitors.
A SGLT2 Inhibitor attorney may be able to provide a free consultation to review your case and recommend a course of action.
Ketoacidosis is a serious condition that can result in costly medical bills, lost income and pain and suffering. Don’t wait to learn more about your legal rights and options for compensation.
Type 2 Diabetes Drugs
What do you do when the drug that’s supposed to heal you ends up hurting you instead?
That’s a question some diabetes patients are grappling with. The popular drugs Onglyza, Byetta and Januvia are among the medicines that have been linked to serious conditions such as pancreatic cancer, thyroid cancer and heart failure.
Have you or a loved one been diagnosed with cancer or experienced heart problems after taking these or another diabetes drug?
A Type 2 Diabetes drug lawyer may be able to help.
There are questions about whether pharmaceutical companies should have done more to warn patients of potential risks. If it’s determined companies are liable, affected patients may receive money to pay for the following:
- Medical bills
- Lost income
- Pain and suffering
An attorney can guide you through the process of filing for compensation.
Already, some court cases have been filed against drug manufacturers, as some evidence already points to a link between some Type 2 Diabetes drugs and life-threatening ailments.
Back in 2013, the Food and Drug Administration began investigating claims that a class of drugs called incretin mimetic drugs was linked to pancreatitis and pre-cancerous changes to the pancreas. Incretin mimetic drugs include some of the most popular Type 2 Diabetes drugs:
- Exenatide (Brand Names: Byetta and Bydureon)
- Liraglutide (Brand Name: Victoza)
- Sitagliptin (Brand Names: Januvia, Janumet, Janumet XR and Juvisync)
- Saxagliptin (Brand Names: Onglyza and Kombiglyze XR)
- Alogliptin (Brand Names: Nesina, Kazano and Oseni)
- Linagliptin (Brand Names: Tradjenta and Jentadueto)
However, that’s not the only problem allegedly found with these drugs. The FDA also held hearings in 2015 on whether Onglyza should have a warning on its label about a potential risk for heart failure. One study found Onglyza and other saxagliptin patients were 27 percent more likely to have heart failure hospitalizations than patients in a control group.
What’s more, the FDA also issued an additional warning for Victoza in 2010. Not only is there evidence the drug may increase the possibility of pancreatitis, it may also be associated with a rare form of thyroid cancer.
What should you do if you took one of these drugs and had health complications?
While every case is different, your first step could be to speak with an Onglyza, Byetta or Januvia attorney to learn more about your legal rights and options.
Japan’s Takeda agrees to pay $2.4B in diabetes drug suit, Mari Yamaguchi, USA Today, April 29, 2015, http://www.usatoday.com/story/money/business/2015/04/29/takeda-diabetes-drug/26559451/
Diabetes Drugs Prescribed to More than 15 Million Americans Raises Risk of Bladder Cancer, Penn Medicine Study Shows, August 13, 2012, http://www.uphs.upenn.edu/news/News_Releases/2012/08/diabetes/
Pioglitazone Information, FDA, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109136.htm
Actos banned in Europe after diabetes drug tied to cancer, Ryan Jaslow, CBS News, June 10, 2011, http://www.cbsnews.com/news/actos-banned-in-europe-after-diabetes-drug-tied-to-cancer/
FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, Food and Drug Administration, May 15, 2015http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm
SGLT2 Inhibitors: The Latest “New Kids on the Block!” Diabetes Care Journal, American Diabetes Association, March 2015, http://care.diabetesjournals.org/content/38/3/352.full
SGLT2 inhibitors: New drug therapy for type 2 diabetes may carry acidosis risk, Drug Topics, September 8, 2015, http://drugtopics.modernmedicine.com/drug-topics/news/sglt2-inhibitors-new-drug-therapy-type-2-diabetes-may-carry-acidosis-risk
Onglyza’s label should flag heart failure risks, FDA panel says; Tracy Staton, Fierce Pharma, April 14, 2015 http://www.fiercepharma.com/story/onglyzas-label-should-flag-heart-failure-risks-fda-panel-says/2015-04-14
Questions and Answers – Safety Requirements for Victoza (liraglutide), FDA,http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm198543.htm
FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes, FDA, http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm